78441-74-4

Usage

Uses

Used in Organic Synthesis:
(4-METHYL-1,2,5-OXADIAZOL-3-YL)METHANOL is used as a building block in the synthesis of various organic compounds. Its unique structure allows it to be a valuable component in creating new and complex organic molecules.
Used in Pharmaceutical Research:
(4-METHYL-1,2,5-OXADIAZOL-3-YL)METHANOL is used as a key intermediate in the development of new drugs and biologically active molecules. Its potential applications in this field are attributed to its ability to contribute to the creation of novel therapeutic agents.
Used in Material Science:
(4-METHYL-1,2,5-OXADIAZOL-3-YL)METHANOL is used as a component in the research and development of new materials. Its unique properties make it a promising candidate for enhancing material performance in various applications.
Used in Agrochemical Research:
(4-METHYL-1,2,5-OXADIAZOL-3-YL)METHANOL is used in the study and development of agrochemicals. Its potential applications in this field highlight its versatility and the possibility of contributing to advancements in agricultural products and technologies.

Upstream product

• 90507-32-7 3-(bromomethyl)-4-methyl-1,2,5-oxadiazole 
• 58677-34-2 4-methyl-1,2,5-oxadiazole-3-carboxylic acid 

Downstream Products

• 90507-35-0 3-formyl-4-methyl-1,2,5-oxadiazole 

Relevant academic research and scientific papers

Synthesis and cardiovascular properties of furazanyl-1,4-dihydropyridines and of furoxanyl analogues

A series of furazanyl- and furoxanyl-1,4-dihydropyridines has been synthesized and tested for their cardiovascular activity. The new compounds showed a modest activity in comparison with nifedipine and some selectivity for the myocardial muscle. The most active compound was diethyl 1,4-dihydro-2,6-dimethyl-4-(3-phenyl-4-furoxanyl)3,5-pyridine dicarboxylate, 4d.

HISTAMINE H2-ANTAGONISTS

Histamine H 2-antagonists of the formula STR1 wherein p is 1 or 2; R 1 is hydroxy, amino, substituted amino or a 5-to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

Nonquaternary cholinesterase reactivators. II. α-Heteroaromatic aldoximes and thiohydroximates as reactivators of ethyl methylphosphonyl-acetylcholinesterase in vitro

We prepared six pairs of α-heteroaromatic aldoximes, RC(=NOH)H, and thiohydroximates, RC(=NOH)S(CH2)2N(C2H5)2, where R represents various oxadiazole and thiadiazole rings. Each compound was characteri

THIADIAZOLE HISTAMINE H2-ANTAGONISTS

Histamine H 2-antagonists of the formula STR1 wherein p is 1 or 2; R 1 is hydroxy, amino, substituted amino or a 5-to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

CHEMICAL COMPOUNDS

Histamine H 2-antagonists of the formula STR1 wherein p is 1 or 2; R 1 is hydroxy, amino, substituted amino or a 5-to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.